Article
Neurosciences
Adam Wisniewski, Joanna Sikora, Aleksandra Karczmarska-Wodzka, Joanna Bugieda, Karolina Filipska, Robert Slusarz
Summary: This study found that the dynamics of platelet reactivity over time can more accurately predict the clinical outcomes of ischemic stroke. A favorable dynamic was associated with milder clinical conditions and better functional statuses, while an unfavorable dynamic was linked to early neurological deterioration. Unfavorable dynamics, especially in combination with high baseline platelet reactivity, were independent predictors of severe clinical conditions, deterioration risk, and poor early and late prognosis.
Article
Neurosciences
Yanjie Xu, Weiqi Chen, Lingling Jiang, Yicong Wang, Xingquan Zhao, Liping Liu, Dongxiao Yao, Lei Guo, Yongjun Wang, Yuesong Pan, Yilong Wang
Summary: In patients with mild stroke or TIA, both ticagrelor and clopidogrel decreased platelet function in poor aspirin responders. Poor aspirin response was not sufficient to reduce the risk of recurrent stroke with ticagrelor or clopidogrel, but may have a protective effect on clinically relevant major bleeding.
JOURNAL OF STROKE & CEREBROVASCULAR DISEASES
(2022)
Article
Pharmacology & Pharmacy
Rene M'Pembele, Samantha Ahlbrecht, Carolin Helten, Philipp Mourikis, David Naguib, Saif Zako, Kajetan Trojovsky, Ragnar Huhn, Tobias Petzold, Thomas Hohlfeld, Tobias Zeus, Malte Kelm, Lisa Dannenberg, Amin Polzin
Summary: This study compared the antiplatelet effects of clopidogrel and ASA and found that impaired pharmacodynamic response (high on-treatment platelet reactivity) was more frequent with clopidogrel than ASA. Therefore, it is recommended to test the effect of ASA in combination with OAC post-PCI.
Article
Hematology
George A. Mason, David J. Rabbolini
Summary: Platelet dysfunction may increase bleeding risk, while increased platelet reactivity on antiplatelet agents may increase thrombosis risk. Platelet function testing can help reduce these risks and guide treatment strategies.
SEMINARS IN THROMBOSIS AND HEMOSTASIS
(2021)
Article
Clinical Neurology
Huihui Lv, Zidong Yang, Haibo Wu, Mingyuan Liu, Xiaowei Mao, Xu Liu, Hongyan Ding, Zhuqing Shi, Yang Zhou, Qianyun Liu, Yongkang Zhang, Yinting Zhou, Kai Chen, Zezhi Li, Qiang Dong, Jianpeng Ma, Yan Han
Summary: The study aimed to explore the value of high on-treatment platelet reactivity (HTPR) in predicting long-term clinical outcomes for stroke patients. The results showed a significant association between HTPR and ischemic events, and patients with CYP2C19 loss-of-function allele were more likely to present with HTPR and had a higher risk of the primary endpoint.
TRANSLATIONAL STROKE RESEARCH
(2022)
Article
Clinical Neurology
X. Wang, L. Luo, Y. Wang, Z. An
Summary: This study evaluated the impact of platelet function testing-guided antiplatelet therapy versus standard antiplatelet therapy in patients undergoing endovascular treatment for intracranial aneurysms. The results showed that platelet function testing-guided therapy significantly reduced the incidence of symptomatic thromboembolic events without any increase in hemorrhagic events. These findings have important clinical implications for adjusting individualized antiplatelet treatment.
AMERICAN JOURNAL OF NEURORADIOLOGY
(2023)
Article
Medicine, General & Internal
Julia Gruttemeier, Yves Cottin, Hermann Yao, Emmanuel De Maistre, Maud Maza, Laurent Bonello, Marc Laine, Noemie Resseguier, Marianne Zeller, Laurence Camoin-Jau, Franck Paganelli
Summary: This study aimed to evaluate platelet reactivity inhibition in ACS patients undergoing PCI with oral triple antithrombotic therapy. The results showed that VASP index failed to predict bleeding and major adverse cardiovascular events, suggesting the need for prioritizing direct acting OAC over VKA in TAT regimen.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Peripheral Vascular Disease
Hiroki Goto, Yuichi Saito, Tadahiro Matsumoto, Takanori Sato, Daichi Yamashita, Sakuramaru Suzuki, Shinichi Wakabayashi, Hideki Kitahara, Koichi Sano, Yoshio Kobayashi
Summary: The study evaluated the differential impact of clinical factors on ischemic outcomes in patients with acute myocardial infarction treated with clopidogrel and prasugrel. The results showed that clinical factors included in the HHD-GENE score were associated with an increased risk of major cardiovascular events in patients on P2Y12 inhibitors, while the clinical factors in the ABCD-GENE score had lower predictive value for ischemic outcomes.
JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS
(2023)
Article
Cardiac & Cardiovascular Systems
Silvia Lee, Patricia P. Wadowski, Timothy Hoberstorfer, Constantin Weikert, Joseph Pultar, Christoph W. Kopp, Simon Panzer, Thomas Gremmel
Summary: The study found that hyperuricemia is associated with increased residual platelet reactivity in patients treated with clopidogrel and prasugrel, but not in those treated with ticagrelor.
CARDIOVASCULAR DRUGS AND THERAPY
(2021)
Article
Hematology
G. Simonte, G. Guglielmini, E. Falcinelli, G. Isernia, A. M. Mezzasoma, P. Gresele, M. Lenti
Summary: This study aims to evaluate the association between high-on-treatment platelet reactivity (HTPR) in patients on aspirin plus clopidogrel therapy after carotid artery stenting (CAS) and subsequent major adverse cardiovascular events (MACE). The results demonstrate that HTPR has predictive value for MACE, with HTPR to three different assays being the most effective predictor.
THROMBOSIS RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Youqi Zhang, Jennifer W. Chou, Wan-Ting Huang, Katrina Derry, Doug Humber
Summary: The review explores platelet functional testing in patients with PAD receiving oral P2Y(12) inhibitors, with VerifyNow PRU test being the most commonly used. There is controversy over the optimal PRU value correlating with cardiovascular outcomes. Despite attempts to define a laboratory threshold for suboptimal response to antiplatelet therapy, adjusting regimens based on P2Y(12) reactivity values has not shown to reduce adverse cardiovascular outcomes.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
(2022)
Article
Clinical Neurology
Yukiko Enomoto, Kenji Shoda, Daisuke Mizutani, Hirofumi Matsubara, Yusuke Egashira, Toru Iwama
Summary: This study evaluated the antiplatelet response in patients with acute ischemic stroke (AIS) after receiving a loading dose of clopidogrel and found that the residual platelet reactivity at 24 hours after administration was higher in AIS patients compared to patients with other cerebrovascular diseases. Additionally, a majority of AIS patients were identified as hypo-responders. However, this result has poor specificity in predicting clinical ischemic events.
FRONTIERS IN NEUROLOGY
(2022)
Article
Hematology
Lianghong Ying, Jing Wang, Juan Li, Jianzhen Teng, Xiaofeng Zhang, Inam Ullah, Abdus Samee, Ke Xu, Jun Chen, Lei Xu, Hui Zhu, Jimin Li, Lu Yang, Fei Wang, Yuansheng Fan, Jing Zhang, Yi Lu, Xiaoxuan Gong, Lu Shi, John W. Eikelboom, Chunjian Li
Summary: In patients with post-PCI HOPR, one month of intensified antiplatelet therapy can significantly reduce the proportion of persistent HOPR and decrease the rate of major adverse cardiovascular events without increasing the risk of bleeding.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Cardiac & Cardiovascular Systems
Zehao Zhao, Shutong Dong, Tienan Sun, Kangning Han, Xin Huang, Meishi Ma, Shiwei Yang, Yujie Zhou
Summary: The study found that elevated levels of free fatty acids are associated with higher residual platelet reactivity when using clopidogrel, and are closely related to metabolic abnormalities in patients with coronary artery disease.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Jiawen Li, Deshan Yuan, Lin Jiang, Xiaofang Tang, Jingjing Xu, Ying Song, Jue Chen, Shubin Qiao, Yuejin Yang, Runlin Gao, Bo Xu, Jinqing Yuan, Xueyan Zhao
Summary: In PCI patients treated with clopidogrel, leukocyte count and hs-CRP were found to be independent predictors of platelet reactivity, with high leukocyte count associated with more LTPR and high hs-CRP associated with more HTPR. This study provides new insights for individualized antiplatelet therapy strategies.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2021)
Review
Cardiac & Cardiovascular Systems
Ludovic Allard, Benedikt Bernhard, Stephan Windecker, Marco Valgimigli, Christoph Graeni
Summary: Despite improvements in the management of ischaemic heart disease, left ventricular thrombus remains a serious issue in patients with myocardial infarction. Echocardiography is commonly used for diagnostic detection, but cardiac magnetic resonance and cardiac computed tomography angiography offer higher diagnostic accuracy. Optimal selection of anticoagulation is necessary to reduce morbidity and mortality associated with left ventricular thrombus, while balancing the risk of bleeding.
EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES
(2022)
Article
Cardiac & Cardiovascular Systems
Juan F. Iglesias, Dik Heg, Marco Roffi, Sophie Degrauwe, David Tueller, Olivier Muller, Miriam Brinkert, Stephane Cook, Daniel Weilenmann, Christoph Kaiser, Florim Cuculi, Marco Valgimigli, Peter Juni, Stephan Windecker, Thomas Pilgrim
Summary: There was no difference in long-term outcomes between ACS patients treated with thin-strut biodegradable polymer sirolimus-eluting stents and durable polymer everolimus-eluting stents at 5 years.
CARDIOVASCULAR REVASCULARIZATION MEDICINE
(2022)
Letter
Cardiac & Cardiovascular Systems
Matthew J. Price, Doug N. Gibson, Saibal Kar
Article
Cardiac & Cardiovascular Systems
Francesco Costa, Claudio Montalto, Mattia Branca, Sung-Jin Hong, Hirotoshi Watanabe, Anna Franzone, Pascal Vranckx, Joo-Yong Hahn, Hyeon-Cheol Gwon, Fausto Feres, Yangsoo Jang, Giuseppe De Luca, Elvin Kedhi, Davide Cao, Philippe Gabriel Steg, Deepak L. Bhatt, Gregg W. Stone, Antonio Micari, Stephan Windecker, Takeshi Kimura, Myeong-Ki Hong, Roxana Mehran, Marco Valgimigli
Summary: The study evaluated the impact of an abbreviated dual antiplatelet therapy (DAPT) regimen in high bleeding risk patients after percutaneous coronary intervention (PCI), using existing evidence. It found that a shorter DAPT duration (1-3 months) reduced bleeding and cardiovascular mortality without increasing ischemic events in these patients.
EUROPEAN HEART JOURNAL
(2023)
Editorial Material
Cardiac & Cardiovascular Systems
Antonio Landi, Anna Giulia Pavon, Marco Valgimigli
Review
Cardiac & Cardiovascular Systems
Claudio Montalto, Francesco Costa, Sergio Leonardi, Antonio Micari, Jacopo A. Oreglia, Pascal Vranckx, Davide Capodanno, Jurrien ten Berg, Renato D. Lopes, Marco Valgimigli
Summary: In patients with concomitant indication to oral anticoagulation, shortening dual antiplatelet therapy duration can reduce bleeding risk without increasing major adverse cardiovascular events.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Antonio Landi, Marco Valgimigli
Article
Cardiac & Cardiovascular Systems
Antonio Landi, Dik Heg, Enrico Frigoli, Pascal Vranckx, Stephan Windecker, Patrick Siegrist, Guillaume Cayla, Adrian Wlodalczak, Stephane Cook, Ivan Gomez-Blazquez, Yair Feld, Park Seung-Jung, Martin Mates, Chaim Lotan, Sengottuvelu Gunasekaran, Mamoru Nanasato, Rajiv Das, Henning Kelbaek, Emmanuel Teiger, Javier Escaned, Yuki Ishibashi, Gilles Montalescot, Hitoshi Matsuo, Dragan Debeljacki, Pieter C. Smits, Marco Valgimigli
Summary: This study investigated the clinical outcomes and treatment selection of antiplatelet therapy (APT) after percutaneous coronary intervention (PCI). The results showed that there was no difference in net adverse clinical outcomes and major adverse cardiac and cerebral events between abbreviated and standard APT at 15 months, but abbreviated APT had a lower risk of bleeding.
JACC-CARDIOVASCULAR INTERVENTIONS
(2023)
Article
Cardiac & Cardiovascular Systems
Antonio Landi, Adrian Wlodarczak, Ralph Tolg, Henning Kelbaek, Jacek Legutko, Stefano Galli, Matthieu G. Godin, Gabor G. Toth, Thibault Lhermusier, Benjamin Honton, Peter Laurenz Dietrich, Francis Stammen, Bert Ferdinande, Johanne Silvain, Davide Capodanno, Guillaume Cayla, Marco Valgimigli
Summary: The BIOFLOW-DAPT trial is investigating the safety of the Orsiro Mission stent compared to the Resolute Onyx stent in high bleeding risk patients. Patients are initially treated with one month of dual antiplatelet therapy (aspirin and a P2Y(12) inhibitor), followed by single antiplatelet therapy. The primary endpoint is the occurrence of cardiac death, myocardial infarction, and stent thrombosis within one year.
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
(2023)
Article
Cardiac & Cardiovascular Systems
Marco Valgimigli, Victor Aboyans, Dominick Angiolillo, Dan Atar, Davide Capodanno, Sigrun Halvorsen, Stefan James, Peter Juni, Vijay Kunadian, Antonio Landi, Sergio Leonardi, Roxana Mehran, Gilles Montalescot, Eliano Pio Navarese, Josef Niebauer, Angelo Oliva, Raffaele Piccolo, Susanna Price, Robert F. Storey, Heinz Voeller, Pascal Vranckx, Stephan Windecker, Keith A. A. Fox
Summary: Multiple guidelines and consensus papers have been used to address the role of antithrombotic strategies in patients with established coronary artery disease (CAD). To update clinicians on the best antithrombotic strategies for these patients, the authors conducted a consensus initiative. They systematically reviewed and performed meta-analyses using both direct and indirect comparisons to inform their recommendations.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Eliano Pio Navarese, Antonio Landi, Angelo Oliva, Raffaele Piccolo, Victor Aboyans, Dominick Angiolillo, Dan Atar, Davide Capodanno, Keith A. A. Fox, Sigrun Halvorsen, Stefan James, Peter Juni, Vijay Kunadian, Sergio Leonardi, Roxana Mehran, Gilles Montalescot, Josef Niebauer, Susanna Price, Robert F. Storey, Heinz Voller, Pascal Vranckx, Stephan Windecker, Marco Valgimigli
Summary: Two network meta-analyses were conducted to evaluate all available antithrombotic treatments within or after 12 months following coronary revascularization and/or acute coronary syndrome. Ticagrelor monotherapy showed lower cardiovascular mortality risk within 12 months, and P2Y(12) monotherapy, especially ticagrelor, was associated with lower risk of myocardial infarction beyond 12 months. Aspirin and rivaroxaban 2.5 mg were most effective in reducing stroke risk, with a more acceptable bleeding risk than VKA.
EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY
(2023)
Article
Cardiac & Cardiovascular Systems
Marco Valgimigli, Adrian Wlodarczak, Ralph Toelg, Bela Merkely, Henning Kelbaek, Jacek Legutko, Stefano Galli, Matthieu Godin, Gabor G. Toth, Thibault Lhermusier, Benjamin Honton, Peter Laurenz Dietrich, Francis Stammen, Bert Ferdinande, Johanne Silvain, Davide Capodanno, Guillaume Cayla
Summary: This study aimed to compare the safety and effectiveness of biodegradable-polymer sirolimus-eluting stents with durable-polymer zotarolimus-eluting stents in patients at high bleeding risk receiving abbreviated dual antiplatelet therapy after percutaneous coronary intervention (PCI). The results showed that the use of biodegradable-polymer sirolimus-eluting stents was noninferior to the use of durable-polymer zotarolimus-eluting stents in terms of the composite outcome of death from cardiac causes, myocardial infarction, or stent thrombosis at 1 year.
Review
Cardiac & Cardiovascular Systems
Thomas A. Meijers, Adel Aminian, Marco Valgimigli, Joseph Dens, Pierfrancesco Agostoni, Juan F. Iglesias, Gabriele L. Gasparini, Arnold H. Seto, Shigeru Saito, Sunil V. Rao, Niels van Royen, Emmanouil S. Brilakis, Maarten A. H. van Leeuwen
Summary: The outcomes of chronic total occlusion percutaneous coronary intervention have significantly improved in the past decade, with a focus on improving procedural safety. Vascular access site bleeding is a common complication, and various strategies have been implemented to reduce its occurrence. This state-of-the-art review provides an overview of the current evidence on optimal vascular access strategies for chronic total occlusion percutaneous coronary intervention.
CIRCULATION-CARDIOVASCULAR INTERVENTIONS
(2023)
Article
Cardiac & Cardiovascular Systems
Alessandro Spirito, Marco Valgimigli, Davide Cao, Usman Baber, Shamir R. Mehta, C. Michael Gibson, Gabriel P. Steg, Samin K. Sharma, Ridhima Goel, Kurt Huber, Vijay Kunadian, Javier Escaned, Anna Franzone, Han Yaling, Timothy Collier, Upendra Kaul, Ran Kornowski, Mitchell Krucoff, David Moliterno, Samantha Sartori, Ruth Owen, Zhongjie Zhang, George D. Dangas, Adnan Kastrati, Dominick J. Angiolillo, David J. Cohen, Pascal Vranckx, Stephan Windecker, Stuart Pocock, Roxana Mehran
Summary: BP-BES is associated with lower risk of major adverse cardiovascular events and target-vessel failure compared to other current generation LES in ACS patients.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2023)
Meeting Abstract
Cardiac & Cardiovascular Systems
Mohil Garg, Hector M. Garcia-Garcia, Andrea Teira Calderon, Jaytin Gupta, Shrayus Sortur, Molly B. Levine, Andrea Picchi, Gennaro Sardella, Marianna Adamo, Enrico Frigoli, Ugo Limbruno, Stefano Rigattieri, Roberto Diletti, Giacomo Boccuzzi, Marco Zimarino, Marco Contarini, Filippo Russo, Paolo Calabro, Giuseppe Ando, Ferdinando Varbella, Stefano Garducci, Cataldo Palmieri, Carlo Briguori, Jorge Sanz Sanchez, Marco Valgimigli
JACC-CARDIOVASCULAR INTERVENTIONS
(2023)